{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-003859","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.025909+00:00","generated_at":"2026-05-28T05:29:29.386713+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Disc Medicine discloses ITGC material weakness; outlines bitopertin NDA plan and 2025 milestones","bullets":["Material weakness in ITGC over key financial IT systems; no misstatements identified to date.","Bitopertin NDA submission plans to be discussed after Type C FDA meeting in Q1 2025; potential accelerated approval for EPP.","Initial phase 2 data for DISC-0974 in myelofibrosis anemia expected H2 2025; multiple-dose CKD data also H2 2025.","Phase 2 trial of DISC-3405 in polycythemia vera planned to start H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-003859","json":"https://secwatch.observer/filing/0000950170-25-003859.json","markdown":"https://secwatch.observer/filing/0000950170-25-003859.md","text":"https://secwatch.observer/filing/0000950170-25-003859.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000095017025003859/0000950170-25-003859-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000095017025003859/iron-20250110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:29:29.386713+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}